Crossmark

Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion

Crossref DOI link: https://doi.org/10.1007/s00262-016-1836-3

Published Online: 2016-04-20

Published Print: 2016-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Du Four, Stephanie

Maenhout, Sarah K.

Benteyn, Daphné

De Keersmaecker, Brenda

Duerinck, Johnny

Thielemans, Kris

Neyns, Bart

Aerts, Joeri L.
Funding

Funding for this research was provided by:

Agentschap voor Innovatie door Wetenschap en Technologie (BE) (121325)

Agentschap voor Innovatie door Wetenschap en Technologie (BE) (111010)

research grant Emmanuel van der Schueren from the Vlaamse Liga Tegen Kanker

Fonds Wetenschappelijk Onderzoek (BE) (G023411N)

Hercules Foundation (UABR/09/002)
License Information

Text and Data Mining valid from 2016-04-20

Document is current

Any future updates will be listed below